Focused On-demand Library for Endoribonuclease ZC3H12A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q5D1E8

UPID:

ZC12A_HUMAN

Alternative names:

Monocyte chemotactic protein-induced protein 1; Regnase-1; Zinc finger CCCH domain-containing protein 12A

Alternative UPACC:

Q5D1E8; D3DPT0; Q6I9Z1; Q9H5P1

Background:

Endoribonuclease ZC3H12A, also known as Regnase-1, plays a pivotal role in cellular processes including inflammatory response, immune homeostasis, and angiogenesis. It functions by degrading mRNAs of cytokines and other genes involved in inflammation and immune activation. Additionally, ZC3H12A regulates microRNA biogenesis, affecting angiogenesis and the ubiquitination of cellular proteins.

Therapeutic significance:

Understanding the role of Endoribonuclease ZC3H12A could open doors to potential therapeutic strategies. Its involvement in key cellular processes and disease mechanisms, such as inflammation and immune response, positions it as a target for developing treatments for inflammatory and autoimmune diseases.